全文获取类型
收费全文 | 137632篇 |
免费 | 9393篇 |
国内免费 | 803篇 |
专业分类
耳鼻咽喉 | 634篇 |
儿科学 | 3281篇 |
妇产科学 | 2528篇 |
基础医学 | 10180篇 |
口腔科学 | 4904篇 |
临床医学 | 28298篇 |
内科学 | 20916篇 |
皮肤病学 | 1931篇 |
神经病学 | 8046篇 |
特种医学 | 2152篇 |
外国民族医学 | 1篇 |
外科学 | 17937篇 |
综合类 | 8227篇 |
现状与发展 | 1篇 |
一般理论 | 68篇 |
预防医学 | 20724篇 |
眼科学 | 1415篇 |
药学 | 8874篇 |
137篇 | |
中国医学 | 3038篇 |
肿瘤学 | 4536篇 |
出版年
2024年 | 310篇 |
2023年 | 3085篇 |
2022年 | 3991篇 |
2021年 | 6097篇 |
2020年 | 5601篇 |
2019年 | 9352篇 |
2018年 | 9389篇 |
2017年 | 6967篇 |
2016年 | 4213篇 |
2015年 | 4006篇 |
2014年 | 7254篇 |
2013年 | 8088篇 |
2012年 | 5415篇 |
2011年 | 5758篇 |
2010年 | 4400篇 |
2009年 | 4266篇 |
2008年 | 4009篇 |
2007年 | 4096篇 |
2006年 | 3482篇 |
2005年 | 2906篇 |
2004年 | 2427篇 |
2003年 | 2016篇 |
2002年 | 1483篇 |
2001年 | 1436篇 |
2000年 | 1235篇 |
1999年 | 1105篇 |
1998年 | 824篇 |
1997年 | 681篇 |
1996年 | 600篇 |
1995年 | 491篇 |
1994年 | 434篇 |
1993年 | 394篇 |
1992年 | 311篇 |
1991年 | 284篇 |
1990年 | 223篇 |
1989年 | 194篇 |
1987年 | 171篇 |
1985年 | 2913篇 |
1984年 | 3443篇 |
1983年 | 2907篇 |
1982年 | 3364篇 |
1981年 | 3055篇 |
1980年 | 2541篇 |
1979年 | 2517篇 |
1978年 | 2071篇 |
1977年 | 1543篇 |
1976年 | 1999篇 |
1975年 | 1520篇 |
1974年 | 1326篇 |
1973年 | 1275篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
91.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
92.
93.
94.
Jinghe Lang 《中国医学科学杂志(英文版)》2022,37(2):91-94
Considering the limitations of medical science and the risks associated with medical treatments, we need to re-examine the connotation of medical science from the perspective of philosophy. Medical science is the natural expression of human kindness and human nature of rescuing the dying and healing the wounded. It is a combination of the natural sciences, social sciences, and humanities. From the perspectives of medical philosophy and humanistic care, this article expounds the concepts and ideas of evidence-based, translational, and precision medicine in modern medicine and emphasizes the importance of avoiding new technical bureaucracy, paying attention to achieving a holistic view and systematic understanding, and avoiding biases in development because of the loss of the humanistic spirit in modern medical practice. 相似文献
95.
96.
97.
98.
99.
100.